Traumatic Brain Injury Associated With Increased Risk of Brain Cancer

Traumatic brain injury (TBI) has been linked to poor long-term outcomes in the veteran population, including cardiovascular disease, dementia, epilepsy and mental health issues. A new study of post-9/11 veterans provides evidence of yet another concerning effect of TBI—an increased, although still low, risk of brain cancer.

Social Avoidance, Other Deficits Appear to Be Features of Schizophrenia, Bipolar Disorder, Not Just the Consequences of Social Isolation

While individuals with schizophrenia and bipolar disorder often have difficulty with relationships and being part of a community, a recent study involving U.S. veterans has found that social cognitive deficits and high social avoidance motivation appear to be actual features of the clinical conditions and not the result of living in social isolation.

Overall Survival Improves With Adjuvant Pembrolizumab in RCC

A third prespecified interim analysis of the KEYNOTE-564 trial has determined that adjuvant pembrolizumab after surgery was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery.

VA Looks Deeper at Treatment Selection in Metastatic Prostate Cancer

Veterans face twice the risk of prostate cancer compared to those who have never served, with approximately 15,000 veterans diagnosed with the disease annually. Breakthroughs in treatment have allowed those patients to live longer than ever and swelled the number of veterans with prostate cancer receiving care through the VHA to nearly 500,000.

Editorial Director

Thanks to cutting-edge efforts to use targeted testing and strict guideline-adherence, the care of patients with serious illnesses is arguably better than ever at the VA and military healthcare systems.

Targeted Therapies for CLL Widely Used at VA; Prolonged Survival

U.S. military veterans with chronic lymphocytic leukemia (CLL) routinely received therapies in line with current evidence-based treatment practices over the past two decades, and those who were treated with targeted therapies had longer overall survival, according to a national VA study with more than 20 years of clinical data.